# Actimis Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/actimis-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.actimis.com
- Total disclosed funding: $6M
- Latest round: Series A (Apr 28, 2005)
- Investors on record: 2

## About

Actimis Pharmaceuticals is engaged in the registration and transfer of premium domain names, providing essential services for businesses and individuals looking to enhance their online presence.Actimis Pharmaceuticals specializes in domain name registration and transfer services. The company, founded by Kevin Bacon, is headquartered in San Diego, US. In June 2008, Boehringer Ingelheim acquired Actimis Pharmaceuticals. The latest funding round occurred in the same year, where they raised USD 1.50 mn in VENTURE DEBT, bringing the total amount raised to USD 6.00 mn.Actimis.com primarily offers domain name registration and transfer services, focusing on the sale of premium domain names. Their core offering is the Actimis.com domain, available for purchase at a price point of USD 3,595. This service caters to businesses and individuals seeking to establish an online presence, enhance brand visibility, or secure valuable digital assets. The company facilitates a streamlined transfer process, ensuring secure transactions and providing support during the acquisition, targeting entrepreneurs, small to medium-sized enterprises, and established corporations, particularly in North America and Europe.Actimis.com generates revenue primarily through direct sales of domain names, with transactions structured as one-time purchases. Clients engage in straightforward transactions where they pay USD 3,595 to acquire a domain, which includes additional support services such as secure payment processing and transaction assistance. The flagship product, the Actimis.com domain, is central to their revenue model, attracting a diverse clientele. Pricing is transparent, offering clarity in the purchasing process.Actimis Pharmaceuticals plans to utilize its recent funding to enhance its domain name offerings and expand into new markets. The company is developing additional premium domain names aimed at enhancing brand visibility for businesses. They are looking to enter the European market more aggressively by the end of 2024. The recent VENTURE DEBT round will support these initiatives by funding marketing efforts and improving service capabilities.

## Funding rounds

- Series A, Apr 28, 2005, $6M — Sanderling Ventures, Mitsui Global Investment

## Investors

- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series A
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series A